What is SNDX's market cap?

$933.15M, based on the Nov 4 close of $10.45.

Does Syndax Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of SNDX is sold short?

18.0M shares, 21.4% of float, as of Oct 15, 2026.

What sector is SNDX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · SNDXHealthcarePharmaceuticals

Syndax Pharmaceuticals, Inc. (SNDX)

$10.45−26.87%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$10.45▼ 31.92% in range

Nov 4, 2025Low $10.45 · High $25.15Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Syndax Pharmaceuticals closed at $10.45 on Nov 4, down 26.87%, within 0.0% of its 52-week closing low. Volume of 15.1M shares was 4.95× its 20-day average (well above normal).

Split-adjusted performance: -39.8% over one month, -49.4% over six months, -24.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $83.30M, up 81.6% from a year earlier, with a net margin of -59.3%.

Short interest was 18.0M shares at the Oct 15 settlement, down 1.3% from the prior report (21.4% of float, 7.6 days to cover).

Market cap$933.2M89.3M shares

Revenue · quarter$83.3M+81.6% YoY

Diluted EPS$-0.55—

P/E · TTM—P/S 3.2×

Net margin-59.3%Gross 83.2%

Dividend yieldNone

52-week range10.45 – 25.15−58.4% from high

Volume15.1M4.95× 20-day avg

Volatility · 60d84.0%Annualised

Short % of float21.4%7.6 days to cover

Net cash$182.3MCash $427.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −27.0%1M −39.8%3M −47.1%6M −49.4%YTD −50.3%1Y −24.1%3Y −19.9%5Y −43.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum25

Revenue growth84

Net margin45

Value (low P/E)—

Size70

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short18.0M−1.3% vs prior

Days to cover7.6Settled Oct 15

% of float21.4%

Short vol. 10d45.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
SNDXSyndax Pharmaceuticals	$10.45	−26.87%	−49.4%	+81.6%	−59.3%	—	$933.2M
LTGOLatigo Biotherapeutics	$14.04	−3.64%	—	—	—	—	$930.8M	Compare
ANROAlto Neuroscience	$23.30	+2.64%	−4.9%	—	—	—	$914.3M	Compare
JBIOJade Biosciences	$15.04	+3.23%	−40.2%	—	—	—	$956.5M	Compare
SVRASavara	$4.66	−1.89%	−11.6%	—	—	—	$957.4M	Compare
RIGLRigel Pharmaceuticals Inc. (New)	$51.29	+4.97%	+92.3%	−22.6%	22.0%	3.0	$958.1M	Compare
ORICOric Pharmaceuticals	$9.34	−2.61%	+0.4%	—	—	—	$968.1M	Compare
CRVSCorvus Pharmaceuticals	$10.57	+7.53%	−31.6%	—	—	—	$889.2M	Compare
MLTXMoonLake Immunotherapeutics	$11.56	−1.20%	−34.7%	—	—	—	$983.8M	Compare

News about Syndax Pharmaceuticals

All news →

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 2d ago▼ Negative Syndax Announces Participation in November Investor ConferencesGlobeNewswire Inc. · 5d ago▲ Positive Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research · Oct 26, 2026▼ Negative Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026GlobeNewswire Inc. · Oct 26, 2026Neutral Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalZacks Investment Research · Oct 14, 2026▼ Negative

Quick answers

What does Syndax Pharmaceuticals do?: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab.
What is SNDX's market cap?: $933.15M, based on the Nov 4 close of $10.45.
Does Syndax Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of SNDX is sold short?: 18.0M shares, 21.4% of float, as of Oct 15, 2026.
What sector is SNDX in?: Healthcare, in the Pharmaceuticals industry.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

HQ: New York, NY298 employeesListed Mar 3, 2016syndax.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology